MorphoSys AG reported a 50% increase in revenue in 2013, mainly the result of antibody licensing deals with GlaxoSmithKline Plc and Celgene Corp and the sale of its service business AbD Serotec. ---Subscribe to MedNous to access this article--- Company News
